Nordicus Partners Corporation Common Stock（NORD）股票分析

AI 分析 of Nordicus Partners Corporation Common Stock (NORD)

買進

Nordstrom Inc (JWN) is a good buy right now due to its strong financial performance, highlighted by a gross margin of 39.04% and a significant increase in net income from $46 million in Q3 to $166 million in Q4. Additionally, hedge funds have increased their buying activity by 155.36% over the last quarter, indicating strong institutional interest. The main risk is the high debt-to-equity ratio of 229.65%, which could pose challenges if market conditions worsen.

估值指標

Nordicus Partners Corporation Common Stock（NORD）目前預期本益比為 0.00，5 年平均預期本益比為。

預期本益比

5 年均值 P/E

目前P/E

0.00

預期 EV/EBITDA

5 年均值 EV/EBITDA

目前EV/EBITDA

0.00

預期股價營收比

合理

5 年均值 P/S

0.07

目前P/S

0.07

高估

0.08

低估

0.06

NORD 常見問題 —— 由 Alphio AI 解答

Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California. It operates in the Academic & Educational Services sector.

Nordstrom Inc (JWN) is a good buy right now due to its strong financial performance, highlighted by a gross margin of 39.04% and a significant increase in net income from $46 million in Q3 to $166 million in Q4. Additionally, hedge funds have increased their buying activity by 155.36% over the last quarter, indicating strong institutional interest. The main risk is the high debt-to-equity ratio of 229.65%, which could pose challenges if market conditions worsen.